BPC-157 vs Cyclic Glycine-Proline
Extensively Studied vs Moderate Research
compatible Different pathways; BPC-157 promotes tissue repair, cGP modulates IGF-1
Molecular Data
BPC-157 Cyclic Glycine-Proline
Weight 1,419.53 Da 154.17 Da
Half-life <30 minutes Extended stability (more stable than linear GPE precursor)
Chain 15 amino acids 2 amino acids (cyclic)
Type Pentadecapeptide Cyclic dipeptide (2,5-diketopiperazine)
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Cyclic Glycine-Proline
01 Neuroprotection and cognitive enhancement
02 IGF-1 optimization
03 Cardiovascular support
04 Metabolic health improvement
05 Blood-brain barrier penetration
06 Convenient oral administration
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Cyclic Glycine-Proline
20-100 μg daily (or 300mg blackcurrant extract 2x daily) / Once daily, preferably in the morning
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Cyclic Glycine-Proline
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Consult healthcare provider if taking IGF-1 or growth hormone medications
Limited long-term human data available
Not studied in pregnancy
Research Evidence
BPC-157 Cyclic Glycine-Proline
Status Extensively Studied Moderate Research
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.